

05/30/01
U.S. PTO
1046

05-31-01

A
Box
Seq
05/30/01
09/07/0203
1046 U.S. PTO
05/30/01

Docket Number 4-31452A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL 835204315 US
Express Mail Label Number

May 30, 2001
Date of Deposit

Address to: Commissioner for Patents
Box Patent Application
Washington, DC 20231

UTILITY PATENT APPLICATION TRANSMITTAL AND FEE SHEET

Transmitted herewith for filing under 37 CFR §1.53(b) is the utility patent application of

Applicant (or identifier): PAUL L. HALLENBECK
NEERAJA IDAMAKANTI
JOHN L. JAKUBCZAK
MICHAEL KALEKO
MICHELE LYNETTE ROLLENCE
THEODORE SMITH
SUSTAN C. STEVENSON
DAVID A. STEWART

Title: ADENOVIRUS PARTICLES WITH MUTAGENIZED FIBER PROTEINS

Enclosed are:

1. Specification (Including Claims and Abstract) - 43 pages
2. Drawings - 17 sheets
3. Executed Declaration and Power of Attorney (original or copy)
4. Microfiche Computer Program (appendix)
5. Nucleotide and/or Amino Acid Sequence Submission
 - Computer Readable Copy
 - Paper Copy
 - Statement Verifying Identity of Above Copies
6. Preliminary Amendment
7. Assignment Papers (Cover Sheet & Document(s))
8. English Translation of
9. Information Disclosure Statement
10. Certified Copy of Priority Document(s)
11. Return Receipt Postcard
12. Other: Unexecuted Declaration and Power of Attorney; Patent Application Bibliographic Data Sheet

Filing fee calculation:

- Before calculating the filing fee, please enter the enclosed Preliminary Amendment.
 Before calculating the filing fee, please cancel claims

Basic Filing Fee								\$ 710
Multiple Dependent Claim Fee (\$ 270)								\$ 270
Foreign Language Surcharge (\$ 130)								\$
	For	Number Filed		Number Extra			Rate	
Extra Claims	Total Claims	85	-20	65	x \$ 18 =		\$ 1,170	
	Independent Claims	2	-3	0	x \$ 80 =		\$	
						TOTAL FILING FEE	\$ 2,150	


- Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$2,150. An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.16 and §1.17 which may be required in connection with this application, or credit any overpayment, to Deposit Account No. 19-0134 in the name of Novartis Corporation.

Please address all correspondence to the address associated with Customer No. 001095, which is currently:

Thomas Hoxie
 Novartis Corporation
 Patent and Trademark Dept.
 564 Morris Avenue
 Summit, NJ 07901-1027

Please direct all telephone calls to the undersigned at the number given below, and all telefaxes to (301) 258-4620.

Respectfully submitted,


 Geoffrey M. Kary
 Attorney for Applicants
 Reg. No. 31,382
 Tel. No. (301) 258-4640

4832

Date: May 30, 2001

Docket Number	4-31452A
FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
EL 835204315 US Express Mail Label Number	May 30, 2001 Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
 IN RE APPLICATION OF
 HALLENBECK ET AL.
 APPLICATION NO: TO BE ASSIGNED
 FILED: MAY 30, 2001
 FOR: ADENOVIRUS PARTICLES WITH MUTAGENIZED FIBER
 PROTEINS

Commissioner for Patents
 Washington, D.C. 20231

**SUBMISSION OF SEQUENCE LISTING
INCLUDING STATEMENT OF VERIFICATION**


Sir:

Applicants hereby provide a Computer Readable Form of the Sequence Listing as well as the Paper Copy thereof. The undersigned states that the Paper Copy and the Computer Readable Form, submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same.

Respectfully submitted,

Novartis Corporation
 Patent and Trademark Dept.
 564 Morris Avenue
 Summit, NJ 07901-1027

Date: May 30, 2001


 Geoffrey M. Kary
 Attorney for Applicants
 Reg. No. 31,382
 (301) 258-4640